Comparison of Efonidipine 40 mg and Chlorthalidone 12.5 mg combination tablets versus Cilnidipine 10 mg and Chlorthalidone 12.5 mg combination tablets in the management of high blood pressure.

Phase 3

Completed

• Conditions: Health Condition 1: I10- Essential (primary) hypertension

• Registration Number: CTRI/2020/08/027364
• Lead Sponsor: Zuventus Healthcare Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-01-15
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 240

Inclusion Criteria

1. Patients aged �18 years.

2. Patients diagnosed with Stage-I hypertension (SBP/DBP: 140-159/90-99 mmHg) or Stage-II hypertension (SBP/DBP: �160/100 mmHg).

3. Patients able to switch all prior antihypertensive medications safely to study medication (Investigatorââ?¬•s discretion).

4. Patients willing to sign informed consent.

Exclusion Criteria

1. Patients with known hypersensitivity to diuretics or dihydropyridine calcium channel blockers.

2. Patients with history of severe, malignant or secondary hypertension.

3. Patient with cerebrovascular disease in the previous 3 months.

4. Patients with chronic arrhythmia, sick sinus syndrome or sinus bradycardia ( < 50 beats/min).

5. Patients with second- or third-degree atrioventricular block.

6. Women who are pregnant, lactating

Study & Design

• Study Type: Interventional
• Study Design: Not specified